Tandem Diabetes Care, Inc. Forecast, price target & analysts
Tandem Diabetes Care, Inc. Target price 2025 - Analyst rating & recommendation
Tandem Diabetes Care, Inc. Classifications & Recommendation:
Tandem Diabetes Care, Inc. Price Target
| Target Price | $48.35 |
| Price | $21.75 |
| Potential |
122.30%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Tandem Diabetes Care, Inc. 2026 .
The average Tandem Diabetes Care, Inc. target price is $48.35.
This is
122.30%
register free of charge
$75.00
244.83%
register free of charge
$18.00
17.24%
register free of charge
|
|
| A rating was issued by 22 analysts: 16 Analysts recommend Tandem Diabetes Care, Inc. to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Tandem Diabetes Care, Inc. stock has an average upside potential 2026 of
122.30%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 940.20 | 1,006.70 |
| 25.74% | 7.07% | |
| EBITDA Margin | -8.78% | 3.08% |
| 52.71% | 135.09% | |
| Net Margin | -10.36% | -8.06% |
| 65.92% | 22.20% |
20 Analysts have issued a sales forecast Tandem Diabetes Care, Inc. 2025 . The average Tandem Diabetes Care, Inc. sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an Tandem Diabetes Care, Inc. EBITDA forecast 2025. The average Tandem Diabetes Care, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Tandem Diabetes Care, Inc. Analysts have issued a net profit forecast 2025. The average Tandem Diabetes Care, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.47 | -1.22 |
| 57.14% | 17.01% | |
| P/E | negative | |
| EV/Sales | 1.45 |
18 Analysts have issued a Tandem Diabetes Care, Inc. forecast for earnings per share. The average Tandem Diabetes Care, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Tandem Diabetes Care, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Tandem Diabetes Care, Inc....
Current Tandem Diabetes Care, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird | Locked ➜ Locked | Locked | Feb 27 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Feb 27 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 26 2025 |
| Citigroup | Locked ➜ Locked | Locked | Dec 11 2024 |
| Morgan Stanley | Locked ➜ Locked | Locked | Dec 02 2024 |
| Barclays | Locked ➜ Locked | Locked | Nov 08 2024 |
| Baird | Locked ➜ Locked | Locked | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Citigroup: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Dec 02 2024 |
|
Locked
Barclays: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
Baird: Locked ➜ Locked
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
